High-density lipoprotein-based drug discovery for treatment of atherosclerosis (Q38506490)

3 September 2017

1 reference

title

High-density lipoprotein-based drug discovery for treatment of atherosclerosis (English)

1 reference

3 September 2017

1 reference

Yu Du

1

1 reference

3 September 2017

Li Wang

series ordinal

2

1 reference

3 September 2017

Bin Hong

series ordinal

3

1 reference

3 September 2017

language of work or name

English

0 references

publication date

28 May 2015

1 reference

Expert Opinion on Drug Discovery

3 September 2017

1 reference

3 September 2017

10

1 reference

3 September 2017

8

1 reference

3 September 2017

841-855

1 reference

HDL and cardiovascular disease

3 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Novel HDL-directed pharmacotherapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Regulation of high-density lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Reconstituted HDL elicits marked changes in plasma lipids following single-dose injection in C57Bl/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Trying to harness the potential of HDL: wishful thinking or sound strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

HDL and cholesterol: life after the divorce?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

High-density lipoproteins for the systemic delivery of short interfering RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

FAMP, a novel apoA-I mimetic peptide, suppresses aortic plaque formation through promotion of biological HDL function in ApoE-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

A novel approach to oral apoA-I mimetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Transcriptional control of apolipoprotein A-I gene expression in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Substituted benzamides containing azaspiro rings as upregulators of apolipoprotein A-I transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Discovery and characterization of small molecule inhibitors of the BET family bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Honokiol increases ABCA1 expression level by activating retinoid X receptor beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Mycophenolic acid induces ATP-binding cassette transporter A1 (ABCA1) expression through the PPARγ-LXRα-ABCA1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Rutaecarpine suppresses atherosclerosis in ApoE-/- mice through upregulating ABCA1 and SR-BI within RCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Optimization of Rutaecarpine as ABCA1 Up-Regulator for Treating Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

IMB2026791, a xanthone, stimulates cholesterol efflux by increasing the binding of apolipoprotein A-I to ATP-binding cassette transporter A1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

miR-33 links SREBP-2 induction to repression of sterol transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

MiR-33 contributes to the regulation of cholesterol homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

MicroRNAs 185, 96, and 223 repress selective high-density lipoprotein cholesterol uptake through posttranscriptional inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

MicroRNAs: target recognition and regulatory functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Advances in the role of microRNAs in lipid metabolism-related anti-atherosclerotic drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Noncoding RNAs and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

High-throughput luciferase reporter assay for small-molecule inhibitors of microRNA function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Small-molecule inhibitors of microrna miR-21 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Methyl protodioscin increases ABCA1 expression and cholesterol efflux while inhibiting gene expressions for synthesis of cholesterol and triglycerides by suppressing SREBP transcription and microRNA 33a/b levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Chronic administration of proanthocyanidins or docosahexaenoic acid reverses the increase of miR-33a and miR-122 in dyslipidemic obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Novel concepts in HDL pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Cholesteryl ester transfer protein: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

HDL-targeted therapies: progress, failures and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Identification of novel human high-density lipoprotein receptor Up-regulators using a cell-based high-throughput screening assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Characterization of the isoflavone pratensein as a novel transcriptional up-regulator of scavenger receptor class B type I in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Identification of trichostatin A as a novel transcriptional up-regulator of scavenger receptor BI both in HepG2 and RAW 264.7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

MicroRNAs 125a and 455 repress lipoprotein-supported steroidogenesis by targeting scavenger receptor class B type I in steroidogenic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Indolinyl-Thiazole Based Inhibitors of Scavenger Receptor-BI (SR-BI)-Mediated Lipid Transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Reciprocal regulation of inflammation and lipid metabolism by liver X receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Liver X receptors in lipid metabolism: opportunities for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Liver X receptor activation attenuates plaque formation and improves vasomotor function of the aortic artery in atherosclerotic ApoE(-/-) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Role of LXRs in control of lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Induction of ABCA1 and ABCG1 expression by the liver X receptor modulator cineole in macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

LXRα is uniquely required for maximal reverse cholesterol transport and atheroprotection in ApoE-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Identification of a selective agonist for liver X receptor α (LXRα) via screening of a synthetic compound library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Identification of a novel partial agonist of liver X receptor α (LXRα) via screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Recent advances in pharmacotherapy for hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Regulation of apo A-I gene expression by fibrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

HDL cholesterol efflux capacity and incident cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

How can high-throughput screening deliver drugs to treat atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

An abundant dysfunctional apolipoprotein A1 in human atheroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

High density lipoprotein: it's not just about lipid transport anymore

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

High-Density Lipoprotein Proteomics: Identifying New Drug Targets and Biomarkers by Understanding Functionality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Preferential Sphingosine-1-Phosphate Enrichment and Sphingomyelin Depletion Are Key Features of Small Dense HDL3 Particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

Novel mutations in scavenger receptor BI associated with high HDL cholesterol in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1051963

10.1517/17460441.2015.1051963

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference